Skip to main content
Springer Nature Link
Log in
Fig. 2 | American Journal of Clinical Dermatology

Fig. 2

From: Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

Fig. 2
See More

Percentage change from baseline in molluscum lesion counts after treatment with VP-102 or vehicle (CAMP-1 and CAMP-2). Intent-to-treat population; VP-102-treated participants (n = 310) and vehicle-treated participants (n = 218). VP-102-treated participants had a statistically significantly larger decrease in mean percentage change in lesions from baseline visit compared with vehicle-treated participants at each visit beginning after the first treatment through the EOS visit (day 84). Overall, VP-102-treated participants had a 76% decrease in lesions whereas vehicle-treated participants had a decrease of 0.3%. EOS end of study. *p < 0.0001

Back to article page